Y-mAbs Therapeutics, Inc.

NasdaqGS:YMAB Stock Report

Market Cap: US$370.9m

Y-mAbs Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Mike Rossi

Chief executive officer

US$3.1m

Total compensation

CEO salary percentage3.5%
CEO tenure1.1yrs
CEO ownershipn/a
Management average tenure3.7yrs
Board average tenure7yrs

Recent management updates

Recent updates

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Dec 10
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26%

Nov 19
The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26%

Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers

Oct 21

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%

Sep 12
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%

Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)

Aug 12

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Jul 15
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Jun 02
Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Y-mAbs: There's A Ceiling Here Somewhere

May 09

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Mar 14
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Feb 17
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Y-mAbs Therapeutics: A Monoclonal Antibody Play

Jan 14

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

Nov 13
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Jul 16
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

May 13
Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Apr 17
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Mar 22
Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Dec 13
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Aug 13
Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers

Jul 12

Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers

May 30

CEO Compensation Analysis

How has Mike Rossi's remuneration changed compared to Y-mAbs Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$24m

Jun 30 2024n/an/a

-US$25m

Mar 31 2024n/an/a

-US$22m

Dec 31 2023US$3mUS$110k

-US$21m

Compensation vs Market: Mike's total compensation ($USD3.11M) is above average for companies of similar size in the US market ($USD2.22M).

Compensation vs Earnings: Insufficient data to compare Mike's compensation with company performance.

CEO

Mike Rossi (53 yo)

1.1yrs

Tenure

US$3,110,553

Compensation

Mr. Michael Rossi, also known as Mike, serves as Chief Executive Officer, President & Director of Y-mAbs Therapeutics, Inc. since November 06, 2023. He has been Director at Nucleus RadioPharma, Inc. He had...

Leadership Team

NamePositionTenureCompensationOwnership
Michael Rossi
CEO, President & Director1.1yrsUS$3.11mno data
Thomas Gad
Founder9.7yrsUS$2.45m0.58%
$ 2.2m
Susan Smith
Senior VP & Chief Commercial Officer2.9yrsUS$887.28k0.0095%
$ 35.2k
Peter Pfreundschuh
CFO & Treasurerless than a yearno datano data
Joris Wiel Wilms
Senior VP & COO7.1yrsno data0.0021%
$ 7.8k
Torben Lund-Hansen
Senior VP & CTO8.9yrsno data0.12%
$ 427.2k
Courtney Dugan
Vice President of Investor Relationsno datano datano data
Vignesh Rajah
Senior VP & Chief Medical Officer4.5yrsUS$724.92k0.019%
$ 70.3k
Norman D. LaFrance
Chief Development Officerless than a yearno datano data

3.7yrs

Average Tenure

54.5yo

Average Age

Experienced Management: YMAB's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Michael Rossi
CEO, President & Director1.1yrsUS$3.11mno data
Thomas Gad
Founder9.7yrsUS$2.45m0.58%
$ 2.2m
James Healy
Independent Chairman of the Board7.1yrsUS$184.31k0.063%
$ 232.7k
David Gill
Independent Director7yrsUS$180.56k0.0052%
$ 19.3k
Mary Tagliaferri
Directorless than a yearno data0%
$ 0
Johan Wedell-Wedellsborg
Independent Director9.3yrsUS$158.06k0.0052%
$ 19.3k
Ashutosh Tyagi
Independent Director7.1yrsUS$158.06k0.0052%
$ 19.3k
Laura Hamill
Independent Director4.5yrsUS$168.06k0.0052%
$ 19.3k

7.0yrs

Average Tenure

56yo

Average Age

Experienced Board: YMAB's board of directors are considered experienced (7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 11:55
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Y-mAbs Therapeutics, Inc. is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Evan SeigermanBMO Capital Markets Equity Research
Etzer DaroutBMO Capital Markets Equity Research